Iomai and Merck Sign Agreement for Immunostimulant Patch
April 4, 2008
US based Iomai has signed an agreement with Merck & Co., to conduct proof-of-principle preclinical studies evaluating the use of the Iomai needle-free immunostimulant patch.
Merck has the first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine.
Stanley Erck, president and CEO of Iomai, said: “This agreement with Merck allows us to further evaluate the possible applications of our patch. Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more effective vaccines, or vaccines that work at a lower dose.”